Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Novo Nordisk is expanding discounted sales of its Wegovy weight loss drug. Novo Nordisk is also licensing a new weight loss drug from China. Crunching the data, the news looks relatively worse for ...

LONDON, March 27 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...